0.8301
price up icon0.00%   0.000100
 
loading
Schlusskurs vom Vortag:
$0.83
Offen:
$0.83
24-Stunden-Volumen:
477.55K
Relative Volume:
0.72
Marktkapitalisierung:
$114.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-3.7732
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
+0.48%
1M Leistung:
+6.81%
6M Leistung:
-12.09%
1J Leistung:
-30.83%
1-Tages-Spanne:
Value
$0.8201
$0.8465
1-Wochen-Bereich:
Value
$0.805
$0.92
52-Wochen-Spanne:
Value
$0.5526
$1.66

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
Firmenname
Atossa Therapeutics Inc
Name
Telefon
206.588.0256
Name
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Name
Mitarbeiter
13
Name
Twitter
@atossainc
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
ATOS's Discussions on Twitter

Vergleichen Sie ATOS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.8301 114.38M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.69 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
539.04 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.30 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
548.28 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.38 28.51B 3.81B -644.79M -669.77M -6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2018-01-26 Eingeleitet Maxim Group Buy

Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten

pulisher
Jun 15, 2025

Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jun 15, 2025
pulisher
Jun 09, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan

Jun 02, 2025
pulisher
May 30, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 28, 2025

Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 28, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire

May 22, 2025
pulisher
May 20, 2025

Atossa Therapeutics announces issuance of U.S. patent - MSN

May 20, 2025
pulisher
May 20, 2025

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan

May 20, 2025
pulisher
May 18, 2025

HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World

May 18, 2025
pulisher
May 15, 2025

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider

May 14, 2025
pulisher
May 14, 2025

Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 14, 2025
pulisher
May 14, 2025

Phase 2 Trial: New Breast Cancer Drug Achieves 77.7% Tumor Shrinkage with Minimal Side Effects - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit

May 13, 2025
pulisher
May 13, 2025

ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 13, 2025
pulisher
May 10, 2025

Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 08, 2025

Atossa Therapeutics reports progress in breast cancer treatments - MSN

May 08, 2025
pulisher
May 05, 2025

Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com

May 05, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 03, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus

May 02, 2025
pulisher
May 02, 2025

ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News

May 02, 2025
pulisher
May 02, 2025

LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

May 02, 2025

Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Atossa Therapeutics Inc-Aktie (ATOS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Remmel H. Lawrence
Director
Mar 26 '25
Buy
0.70
10,000
7,000
10,257
$20.77
price up icon 0.61%
$35.84
price down icon 0.56%
$21.20
price down icon 0.47%
$97.54
price down icon 3.04%
$108.01
price up icon 1.45%
biotechnology ONC
$243.88
price up icon 0.76%
Kapitalisierung:     |  Volumen (24h):